Hammersmith Medicines Research
London, NW10 7EW, United Kingdom
NCT Number: NCT02792647
The purpose of this study is to investigate the safety and tolerability of IX-01 after multiple doses, and to determine the PK of IX-01 and activity of CYP3A4.
Looking for future studies?
Notify Me18 year–45 year
Male
Interventional
Phase 1
London, NW10 7EW, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Administered orally
Administered orally
Time frame: Baseline to Day 20 (Estimated up to 3 weeks)
Time frame: Pre-dose to 24 hours post dose on Days 1 and 10
Time frame: Pre-dose up to 24 hours post dose on Days 1 and 10
Time frame: Pre-dose to 24 hours post dose on Days 1 and 10
Time frame: Pre-dose on Day 1 and Day 10
Time frame: Pre-dose up to 96 hours post dose on Day 10
Time frame: Pre-dose up to 24 hours post dose on Day 10
Time frame: Pre-dose up to 24 hours post dose on Days 1 and 10
Time frame: Pre-dose to 96 hours post dose on Day 10
Time frame: Pre-dose on Days 2 to 10
Time frame: Pre-dose up to 96 hours post dose on Day 10
Time frame: Pre-dose up to 24 hours post dose on Day 10
Time frame: Pre-dose up to 96 hours post dose on Day 10
Ixchelsis Limited
Industry
A Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose Escalation Study to Investigate the Safety, Toleration, and Pharmacokinetics of Multiple Oral Doses of IX-01 in Healthy Male Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05447078
Healthy Volunteers, Infections
Jackson, Mississippi, United States
View Trial DetailsNCT07513532
Healthy Volunteers
Seattle, Washington, United States
View Trial DetailsNCT07090655
Healthy Volunteers
Brisbane, Australia
View Trial DetailsNCT01915212
Communicable Diseases, DNA Virus Infections
Bethesda, Maryland, United States
View Trial Details